Accuray Introduces the InTempo(TM) Adaptive Imaging System to Address Prostate Motion That Commonly Occurs During Radiation Treatment Delivery

New Capabilities Help to Ensure Prescribed Dose is Delivered to the Prostate

While Precisely Controlling Exposure to Surrounding Healthy Tissue

SUNNYVALE, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today introduced the InTempo(TM) Adaptive Imaging System, which enhances the CyberKnife(R) Robotic Radiosurgery System's ability to continually track and correct for motion of the prostate during treatment.

Studies have confirmed that the prostate can move significantly in only a matter of seconds during treatment delivery. With the introduction of the InTempo System, radiation delivery with the CyberKnife System automatically adapts to patient-specific intra-fraction prostate motion. By intelligently increasing imaging frequency during periods of rapid and erratic prostate movement, the CyberKnife System tailors treatment delivery uniquely to the movements of the prostate throughout the treatment session. This continual assessment of prostate motion combined, with the CyberKnife System's automatic correction for movement in real time, not only helps to ensure prescribed doses are delivered to the prostate; it also helps to ensure surrounding sensitive structures are maximally spared.

With conventional radiation delivery techniques, such as 3D conformal and arcing IMRT, large treatment margins are commonly used to ensure adequate dose coverage in the event a potential prostate shift occurs. This additional dose coverage often encompasses regions of the rectum, bladder, and urethra, increasing the risks of related toxicities and complications.

"Motion of the prostate during treatment has long been recognized as one of the major limiting factors for prostate dose escalation. This motion requires continual monitoring throughout treatment, which only the CyberKnife System can provide," said Eric P. Lindquist, senior vice president and chief marketing officer at Accuray. "The InTempo System takes the treatment of prostate cancer to an entirely new level, giving clinicians added confidence when delivering high-dose, hypofractionated radiation."

With advanced robotic technology, the CyberKnife System utilizes continual image guidance to automatically track, detect, and correct for intra-fraction motion throughout the treatment. In contrast, conventional imaging technologies, such as IGRT and cone-beam CT, can provide a high degree of precision for pre-treatment patient alignment, but the image age - or time between when the set-up image was captured and beam delivery is completed - can be 5 minutes or more. Using such imaging technologies, conventional radiation delivery systems often fail to recognize prostate movements that occur during treatment delivery, potentially resulting in considerable degradation of overall targeting accuracy.

Accuray will highlight the InTempo System at the company's booth #1701 during the 50th American Society for Therapeutic Radiology & Oncology (ASTRO) Annual Meeting September 21-25, 2008 in Boston.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently more than 140 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the year ended June 30, 2008 as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated
CONTACT: Susan Lehman, Rockpoint Public Relations, +1-510-832-6006,
susan@rockpointpr.com; Stephanie Tomei, Public Relations Manager, Accuray
Incorporated, +1-408-789-4234, stomei@accuray.com
Web site: http://www.accuray.com